A study involving 3,620 patients with NSCLC reported that KRAS is a prominent prognostic marker for the survival of patients with lung adenocarcinoma but ineffective for patients with lung small cell carcinoma (Brose et al., 2002). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.